Brief: Ocuphire Pharma Believes Cash On Hand Sufficient To Fund Operations In 2025

Opus Genetics

30/03/2023 14:31

March 30 (Reuters) - Ocuphire Pharma Inc  OCUP.O :
    * OCUPHIRE PHARMA INC - BASED ON CURRENT PROJECTIONS,
MANAGEMENT
BELIEVES PRESENT CASH ON HAND WILL BE SUFFICIENT TO FUND
OPERATIONS INTO 2025
    * OCUPHIRE: PDUFA DATE OF SEPT 28 SET FOR NYXOL IN FIRST
INDICATION, REVERSAL OF PHARMACOLOGICALLY-INDUCED MYDRIASIS; $10
MILLION MILESTONE LINKED TO APPROVAL
    * OCUPHIRE PHARMA INC - LICENSE AND COLLABORATIONS REVENUE
WAS
$39.9 MILLION FOR QUARTER COMPARED TO ZERO
    * OCUPHIRE PHARMA INC QTRLY EARNINGS PER SHARE $1.58

Source text for Eikon:  ID:nGNX1j5F31 
Further company coverage:  OCUP.O 

 ((Reuters.Briefs@thomsonreuters.com;))